Some features of the hemostasis system in pregnant women at risk of developing preeclampsia

V.I. Chermak
Kiev Medical University

The objective: a study of the hemostasis system in pregnant women with a risk of preeclampsia development.

Materials and methods. 100 pregnant women with the risk for preeclampsia (main group) were examined. The risk factors were determined according to the Guideline “Hypertensive Disorders During Pregnancy”, Order No. 676 of the Ministry of Health of Ukraine. The control group contained 50 healthy women with physiological pregnancy. The groups were representative in age and reproductive history.

The following indicators of hemostasis were studied: the platelet system (the number of platelets, their aggregation ability and the total platelet aggregation index (TPAI), the coagulation system (autocoagulation test, thrombin time, prothrombin index, fibrinogen concentration) and the state of the fibrinolysis system which was determined by such indicators: plasma level of free heparin, activity of antithrombin III, indicators of ethanol and protamine sulfate tests, concentration of soluble fibrin in blood plasma.

Results. In pregnant women with a risk of preeclampsia, there are changes in platelet hemostasis indicators: a significant decrease in the number of platelets and a significant (p<0.05) increase in platelet aggregation ability, there is a tendency to an increase in TPAI indicators. In the main group a significant increase in the fibrinogen concentration, plasma lysis indicators and a tendency to an increase of the free heparin concentration, a decrease of antithrombin III and, in comparison with the indicators in healthy women, a 3-fold increase in the content of soluble fibrin (p<0.05) were found.

Conclusions. In pregnant women with a risk of preeclampsia development, there are disorders in the vascular-platelet hemostasis, coagulation and fibrinolytic blood systems, namely, a significant tension in the platelet link of the system, an increase in thrombogenic potential, and a sharp inhibition of the fibrinolytic link of hemostasis.

Keywords: pregnancy, preeclampsia, risk groups, hemostasis.
Preeclampsia is the most serious complication of pregnancy. It is known that preeclampsia is a genetically determined disease, which most often develops on the background of concomitant maternal extragenital pathology. The most important background for the preeclampsia occurrence is arterial hypertension and its first stage of development – somatotropic dysfunction of the autonomic nervous system (SDA), or hypertensive type of vascular dystonia [1, 2, 3]. Gestosis on the background of hypertensive type of SDA occurs in 51–88% of cases and is characterized by an earlier manifestation of all symptoms [4, 5, 6]. (V. Radzinsky et al., 2004).

The leading place in the etiopathogenesis of PE is given to the violation of adaptive reactions of the pregnant woman in response to the influence of endogenous and exogenous destabilizing factors (extragenital pathology, urogenital infection, chronic psychoemotional stress) [7, 8, 9, 10].

It is proved that pregnancy is accompanied by a complex of neuroendocrine changes that contribute to the formation of changes in blood flow in the microcirculatory tract, as well as changes in the hemostasis system. Physiological pregnancy is accompanied by a state of hypercoagulation due to an increase of 200% or more in coagulation factors against the background of reduced fibrinolytic and natural anticoagulant activity.

From the second trimester of pregnancy, the activity of procoagulants and platelets increases, the anticoagulant potential of the blood decreases. With the progression of pregnancy there is a significant increase in the concentration of fibrinogen in the blood (over 70%), a decrease in APTT, which indicates an increase in the content of factors of the internal procoagulant chain of the hemostasis system: II, V, IX, X, XI, XII. An increase in PTI in late pregnancy indicates an increase in the activity of coagulation factors II, V, VII, X. An increase of the fibrin degragation products in the serum also indicates an intensification of intravascular coagulation processes [11, 12, 13].

According to the study results of the platelet part of the hemostasis system, it is proved that the aggregation activity of platelets practically does not change during pregnancy, the adhesion of platelets slightly increases [14, 15].

With increasing gestational age in healthy pregnant women, the hemostasis system changes in the direction of increasing blood clotting potential, namely - the rate of blood clotting increases and the structural properties of blood clotting strengthens, the content of PTI in serum increases in late pregnancy with a parallel increase in concentration I, II, VIII, IX, X, XII coagulation factors. The activity of factors XI (precursor of plasma thromboplastin) and XIII (fibrin stabilization) is reduced.

The high hemocoagulation potential of blood during pregnancy is associated with a decrease in its fibrinolytic activity. Changes in fibrinolytic activity of blood during pregnancy are caused by the influence of placental hormones (progestosterone, placental lactogen) on the synthesis of fibrinolysis activators in the vascular endothelium. The number of platelets during pregnancy varies and depends on the degree of hemodilution and utilization of platelets in the placenta, as well as on the individual characteristics of the body. The level of fibrinogen (factor I) increases from 2.6 to 4–5 g/l, starting from the third month of pregnancy, and reaches maximum values on the eve of childbirth, which leads to an increase levels of degradation products and factors VII–X in blood [16, 17].

In the third trimester of pregnancy, and especially on the eve of the childbirth, a state of unstable equilibrium is formed between the blood clotting and fibrinolysis systems. The level of coagulation factors during pregnancy increases: factor I (fibrinogen) – almost 2 times, factors VII (proconvertin), VIII (antihemophilic factor), X (Stewart-Prauer factor) – by 50–100%, factor II (prothrombin) – by 20–40%. At the same time, fibrinolytic activity decreases due to changes in the circulating fibrinolysis proactivators activity, as well as with an increase in the level of fibrinolysis inhibitors. In addition, platelet aggregation abilities changes, which is a leading factor in the genesis of microcirculation disorders during pregnancy and childbirth [1, 8, 16].

In addition, in the II-nd and especially in the III-rd trimesters of pregnancy, the blood flow velocity in
the lower extremities veins is halved due to mechanical obstruction of the venous outflow tract, as well as a decrease in venous wall tone associated with hormonal changes during pregnancy.

At the end of the third trimester, the prothrombin index increases - the activation of the external blood clotting pathway. Fibrinolytic activity of plasma progressively decreases. The concentration of prothrombin (factor II) in early pregnancy does not change. The value of the prothrombin index in % and INR (international normalized ratio) in pregnant women is 85–115% and 0.8–1.2. The normal value of APTT in pregnant women is 28–38 seconds. Indicators of factors V and XII, as well as bleeding time do not change during a normal pregnancy. The platelet count may decrease slightly. The normal value of platelets in pregnant women is 140–400 × 10^9/l.

The indicator under study

The objective: to study the state of the hemostasis system in pregnant women at risk of developing preeclampsia.

Materials and Methods

We examined 100 pregnant women from the risk group of this pregnancy complication (Main group). Determination of risk factors was performed according to the Protocol «Hypertensive disorders during pregnancy», Order № 676 of the Ministry of Health of Ukraine [3]. The survey data from 50 healthy women with physiological pregnancy (Control group) served as a control. The groups were representative in terms of age and reproductive history.

In the above patients, the indicators of all three links of hemostasis were studied: platelet (platelet count, their aggregation capacity and total platelet aggregation index (TPAI), coagulation system (autocoagulation test, thrombin time, prothrombin index, and fibrinogen concentration) and the state of fibrinolysis system, which was managed by the following indicators: plasma lysis, the level of free heparin, the activity of antithrombin III, ethanol and protamine sulfate tests, the concentration of soluble fibrin in blood plasma [18].

Results and Discussion

Indicators of platelet hemostasis of the examined women are shown in table 1.

The results of the study of platelet hemostasis indicate a significant (p<0.05) decrease in platelet count (188.9±11.3×10^9 in the Control and 169.7±9.9×10^9 in the Main group) and a significant (p<0.05) increase of platelet aggregation capacity (respectively 30.9±4.1×10^9 and 41.8±4.5×10^9, respectively, in the Control and Main groups). TPAI indicators tended to increase. Analysis of the obtained indicators of vascular-platelet hemostasis indicates a significant tension of the platelet link of the hemostasis system in pregnant women at risk of developing preeclampsia.

Indicator’s data of the coagulation system in examined patients are shown in table 2.

Analysis of blood coagulation indicators indicates the absence of significant changes (p>0.05) in the indicators of the autocoagulation test mA (89.5±2.5% and 93.2±1.9%, respectively, in the Control and Main groups) and ITA 1.6±0.1% and 1.7±0.2%, respectively, in the Control and Main groups) between groups.

Table 1

<table>
<thead>
<tr>
<th>The indicator under study</th>
<th>Control group (n=50)</th>
<th>Main group (n=100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platelet count (1×10^9)</td>
<td>188.9±11.3</td>
<td>169.7±9.9</td>
</tr>
<tr>
<td>Platelet aggregation (%)</td>
<td>30.9±4.1</td>
<td>41.8±4.5*</td>
</tr>
<tr>
<td>TPAI (%)</td>
<td>39.8±4.2</td>
<td>41.1±2.9</td>
</tr>
</tbody>
</table>

Note: * – p<0.05 between the indicators of the control and main group.
Thrombin time and prothrombin index do not differ (p>0.05) and there is a significant difference (p<0.05) in fibrinogen concentrations (from 4.0±0.2 g/l in Control to 4.8±0.2 g/l in the Main group).

Based on the obtained data, it can be assumed that the coagulation system in pregnant women at risk of pre-eclampsia is in a fairly compensated state, but a significant increase in fibrinogen concentration in pregnant women at risk of preeclampsia indicates an increase in thrombogenic potential of hemostasis in these patients.

Indicators of the fibrinolysis system in pregnant women at risk of preeclampsia are shown in table 3.

Analysis of the results of the pregnant women from the risk group of preeclampsia examination, indicates a significant (p<0.05) increase in plasma lysis (respectively 148.6±4.8 and 227.3±12.6) and a tendency to increase concentrations of free heparin, decrease of AT-III and 3-fold increase in soluble fibrin, decrease in platelets and increase in aggregation capacity, a significant increase in fibrinogen concentrations. The maximum coagulation stress of the hemostasis system in pregnant women at risk of preeclampsia is compensated by activation of the fibrinolysis system (increase in plasma lysis, increase in free heparin concentrations, 3-fold increase in soluble fibrin, decrease in AT-III and 100% positive ethanol test).

It should be noted that the unstable balance of the hemostasis system, which is observed in pregnant women at risk of preeclampsia, should be regarded as the first phase of thrombo-hemorrhagic syndrome (DIC).

Our results of the hemostasis system state in pregnant women at risk of developing preeclampsia indicate the feasibility of using drugs that have a positive effect on the state of the hemostasis system.

**CONCLUSIONS**

In pregnant women at risk of developing preeclampsia there are violations of the hemostasis system, with negative changes in all its parts: vascular-platelet hemostasis, coagulation and fibrinolytic systems.

The revealed violations can be considered as a pathogenetic substantiation of expediency to include the preparations with corrective influence on the system of a hemostasis in a complex of medical actions.

**Table 2**

<table>
<thead>
<tr>
<th>The indicator under study</th>
<th>Control group, n=50</th>
<th>Main group, n=100</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autocoagulation test:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- mА, %</td>
<td>89,5±2,5</td>
<td>93,2±1,9</td>
</tr>
<tr>
<td>- ITA (Index of thrombin inactivation)</td>
<td>1,6±0,1</td>
<td>1,7±0,2</td>
</tr>
<tr>
<td>Thrombin time, sec</td>
<td>10,3±0,4</td>
<td>11,2±0,5</td>
</tr>
<tr>
<td>Prothrombin index, %</td>
<td>99,1±3,5</td>
<td>97,1±2,2</td>
</tr>
<tr>
<td>Fibrinogen, g/l</td>
<td>4,0±0,2</td>
<td>4,8±0,2*</td>
</tr>
</tbody>
</table>

*Note: * – p<0.05 between the indicators of the control and main group.

**Table 3**

<table>
<thead>
<tr>
<th>The indicator under study</th>
<th>Control group, n=50</th>
<th>Main group, n=100</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma lysis (mg/min-l)</td>
<td>148,6±4,8</td>
<td>227,3±12,6*</td>
</tr>
<tr>
<td>Free heparin (sec.)</td>
<td>0,9±0,3</td>
<td>1,4±0,4</td>
</tr>
<tr>
<td>Antithrombin-III (%)</td>
<td>65,6±1,1</td>
<td>56,4±3,2*</td>
</tr>
<tr>
<td>Protamine sulfate test (mg%)</td>
<td>4,6±0,7</td>
<td>3,9±0,4</td>
</tr>
<tr>
<td>Soluble fibrin (+)</td>
<td>0,8±0,2</td>
<td>2,9±0,4*</td>
</tr>
</tbody>
</table>

*Note: * – p<0.05 between the indicators of the control and main group.

**Table 4**

<table>
<thead>
<tr>
<th>The result of study</th>
<th>Control group, n=50</th>
<th>Main group, n=100</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td>82</td>
<td>-</td>
</tr>
<tr>
<td>Weakly positive</td>
<td>10</td>
<td>42</td>
</tr>
<tr>
<td>Positive</td>
<td>8</td>
<td>58</td>
</tr>
</tbody>
</table>

*Note: * – p<0.05 between the indicators of the control and main group.
REFERENCES